The MHRA announced on 14 April 2026 that a single-dose 7.2mg semaglutide (Wegovy) pen has been approved for use in adults with obesity. It joins the existing Wegovy 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg dose options. For UK community pharmacy, which already dispenses Wegovy both on NHS and specialist-initiated private weight-management pathways, the new pen is a device and dose change rather than a wholesale shift in the therapeutic landscape — but it does raise new counselling and stock-management considerations.
This article summarises the approval, situates it alongside existing UK guidance, and flags practical points for community pharmacy teams.
What the MHRA announced
The MHRA confirmed that a single-dose 7.2mg Wegovy pen has been approved for the treatment of adult patients with obesity. The agency noted, as with any new medicine, that the safety and effectiveness of Wegovy will be kept under close review. The 7.2mg dose sits above the previously licensed 2.4mg maintenance dose, reflecting the evidence from higher-dose semaglutide studies published over the last two years suggesting greater weight-loss outcomes at higher doses in selected patients.
Where semaglutide for weight management currently sits in the UK
NICE TA875 recommends semaglutide 2.4mg weekly as an option for weight management in adults with a body mass index (BMI) of 35 kg/m² or more (or 30–34.9 kg/m² with weight-related comorbidities and meeting specific criteria), as part of a specialist weight management service. The recommendation includes a maximum treatment duration of two years under NHS funding.
Outside the NHS, private weight-management services — a fast-growing segment, often delivered through online prescribers and community pharmacy fulfilment — account for a significant share of UK semaglutide supply. Private prescribing is subject to GPhC and MHRA requirements around remote consultation, BMI verification and appropriate clinical assessment.
What the new 7.2mg pen changes
A higher-dose single-use pen has implications across several practical fronts:
Dose escalation pathways
Until now, escalation above 2.4mg on the UK market has required off-label arrangements or reliance on other semaglutide formulations. A licensed 7.2mg option provides a regulated route at a higher dose. The specifics of eligibility, escalation schedule and maintenance are set out in the SmPC — pharmacists should refer to the updated Summary of Product Characteristics before dispensing, not to earlier-dose SmPC information extrapolated upward.
Counselling at dispensing
Semaglutide's side-effect profile is dose-related. At higher doses, the probability and severity of gastrointestinal adverse events — nausea, vomiting, constipation, diarrhoea, reduced appetite — rise. Counselling the first dispensing of a higher-dose pen should cover:
- Expected side effects and how to manage them (small, bland meals; hydration; avoidance of high-fat foods).
- Red flags that require clinical review (persistent vomiting, severe abdominal pain which may indicate pancreatitis, signs of acute gallbladder disease, signs of dehydration).
- Interaction considerations — semaglutide delays gastric emptying and can affect absorption of oral medications taken concurrently.
- Storage and handling of the pen (refrigeration; disposal of used devices in a sharps bin).
- The importance of continued engagement with the weight-management service, not just supply of the drug.
Supply and stock considerations
A new pen presentation entering the UK market adds a line to what is already a complex, supply-sensitive category. Community pharmacies stocking semaglutide products should plan for:
- Multiple pen presentations held concurrently.
- Careful differentiation between Wegovy (weight management) and Ozempic (type 2 diabetes) stock, since both are semaglutide and the supply chain has historically had cross-indication pressure.
- Updated cold-chain and sharps-disposal processes.
- Training refresh for counter and dispensary staff on the new pen.
NHS versus private pathways
NICE-funded semaglutide supply continues to be bound by TA875's criteria. How and when the 7.2mg pen becomes part of NHS provision depends on NICE assessment, NHS England commissioning and service specifications. In the short term, the new pen is likely to appear predominantly via private weight-management services, with NHS access following subject to assessment.
What pharmacists shouldn't do
- Do not substitute between Wegovy dose strengths or between Wegovy and Ozempic without an explicit prescriber instruction. These are distinct licensed products with distinct indications.
- Do not dispense higher doses beyond the prescribed strength. Titration above or below the prescription is a prescriber decision.
- Do not dispense semaglutide for off-label cosmetic weight loss in patients who do not meet the service or clinical criteria — a GPhC focus area for regulatory scrutiny in recent years.
The wider workforce picture
Pharmacy-based delivery of weight-management medicines has been one of the fastest-growing service lines across community pharmacy since 2023. Across the PharmSee database of UK pharmacy vacancies sampled in April 2026, clinical roles at chains with active weight-management offerings frequently list GLP-1 experience or training as a desirable attribute, reflecting the operational importance of this category.
Caveats
This article summarises the MHRA's 14 April 2026 announcement and existing NICE, BNF and NHS England guidance. The definitive clinical reference is the updated SmPC for the new pen. Eligibility, counselling requirements and supply pathways should be based on the SmPC, the relevant PGD or prescription, and the current NHS service specification where applicable.
Sources
- MHRA — Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity (gov.uk, 14 April 2026)
- NICE TA875 — Semaglutide for managing overweight and obesity
- British National Formulary — semaglutide
- NHS England — Weight management services
Find a community pharmacy that dispenses weight-management medicines via PharmSee's pharmacy finder.